Literature DB >> 12477279

Cellular uptake, distribution, and stability of 10-23 deoxyribozymes.

Crispin R Dass1, Edward G Saravolac, Yang Li, Lun-Quan Sun.   

Abstract

The cellular uptake, intracellular distribution, and stability of 33-mer deoxyribozyme oligonucleotides (DNAzymes) were examined in several cell lines. PAGE analysis revealed that there was a weak association between the DNAzyme and DOTAP or Superfect transfection reagents at charge ratios that were minimally toxic to cultured cells. Cellular uptake was analyzed by cell fractionation of radiolabeled DNAzyme, by FACS, and by fluorescent microscopic analysis of FITC-labeled and TAMRA-labeled DNAzyme. Altering DNAzyme size and chemistry did not significantly affect uptake into cells. Inspection of paraformaldehyde-fixed cells by fluorescence microscopy revealed that DNAzyme was distributed primarily in punctate structures surrounding the nucleus and that substantial delivery to the nucleus was not observed up to 24 hours after initiation of transfection. Incubation in human serum or plasma demonstrated that a 3'-inversion modification greatly increased DNAzyme stability (t(1/2) approximately 22 hours) in comparison to the unmodified form (t(1/2) approximately 70 minute). The 3'-inversion-modified DNAzymes remained stable during cellular uptake, and catalytically active oligonucleotide could be extracted from the cells 24 hours posttransfection. In smooth muscle cell proliferation assay, the modified DNAzyme targeting the c-myc gene showed a much stronger inhibitory effect than did the unmodified version. The present study demonstrates that DNAzymes with a 3'-inversion are readily delivered into cultured cells and are functionally stable for several hours in serum and within cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12477279     DOI: 10.1089/108729002761381276

Source DB:  PubMed          Journal:  Antisense Nucleic Acid Drug Dev        ISSN: 1087-2906


  28 in total

1.  RNA cleaving '10-23' DNAzymes with enhanced stability and activity.

Authors:  Steffen Schubert; Deniz C Gül; Hans-Peter Grunert; Heinz Zeichhardt; Volker A Erdmann; Jens Kurreck
Journal:  Nucleic Acids Res       Date:  2003-10-15       Impact factor: 16.971

2.  A novel replicating circular DNAzyme.

Authors:  Fei Chen; Ruijian Wang; Zhe Li; Bin Liu; Xiaoping Wang; Yanhong Sun; Dongyun Hao; Jin Zhang
Journal:  Nucleic Acids Res       Date:  2004-04-28       Impact factor: 16.971

Review 3.  Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection.

Authors:  Crispin R Dass
Journal:  J Mol Med (Berl)       Date:  2004-06-23       Impact factor: 4.599

Review 4.  Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies.

Authors:  Ravinay Bhindi; Roger G Fahmy; Harry C Lowe; Colin N Chesterman; Crispin R Dass; Murray J Cairns; Edward G Saravolac; Lun-Quan Sun; Levon M Khachigian
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

Review 5.  Metal-Dependent DNAzymes for the Quantitative Detection of Metal Ions in Living Cells: Recent Progress, Current Challenges, and Latest Results on FRET Ratiometric Sensors.

Authors:  Kevin Hwang; Quanbing Mou; Ryan J Lake; Mengyi Xiong; Brandalynn Holland; Yi Lu
Journal:  Inorg Chem       Date:  2019-07-31       Impact factor: 5.165

Review 6.  DNAzymes and cardiovascular disease.

Authors:  V L Benson; L M Khachigian; H C Lowe
Journal:  Br J Pharmacol       Date:  2008-05-05       Impact factor: 8.739

Review 7.  Aptamers as Therapeutic Agents: Has the Initial Euphoria Subsided?

Authors:  S K Haßel; G Mayer
Journal:  Mol Diagn Ther       Date:  2019-06       Impact factor: 4.074

8.  DNA Antenna Tile-Associated Deoxyribozyme Sensor with Improved Sensitivity.

Authors:  Amanda J Cox; Hillary N Bengtson; Yulia V Gerasimova; Kyle H Rohde; Dmitry M Kolpashchikov
Journal:  Chembiochem       Date:  2016-09-13       Impact factor: 3.164

9.  Direct anti-metastatic efficacy by the DNA enzyme Dz13 and downregulated MMP-2, MMP-9 and MT1-MMP in tumours.

Authors:  Mei Lin Tan; Peter F M Choong; Crispin R Dass
Journal:  Cancer Cell Int       Date:  2010-03-24       Impact factor: 5.722

10.  Locked nucleic acid modified DNA enzymes targeting early growth response-1 inhibit human vascular smooth muscle cell growth.

Authors:  Roger G Fahmy; Levon M Khachigian
Journal:  Nucleic Acids Res       Date:  2004-04-23       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.